Jasmine Gowarty
Hematology & Oncology · McAllen, TXNPI 1003263732
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,611 of the $3,498 with a category attached, or 74.6%. 35 manufacturers reported payments, led by Novartis at 24.8% of the total. 2025 is the largest year on record at $2,536, more than ten times the $14 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 104 payments — averaging $33.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$869
- Karyopharm Therapeutics Inc.$232
- GSK$198
- Gilead$188
- E.r. Squibb & Sons, L.L.C.$179
- Medtronic$153
- plus $2K from 29 others
Across 2 payments — averaging $9203.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$18K
What the payments were for
- Food & beverage$2,61175%
- Education$1895%
- Other$69820%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $869 |
| Karyopharm Therapeutics Inc. | 7 | $232 |
| GSK | 5 | $198 |
| Gilead | 8 | $188 |
| E.r. Squibb & Sons, L.L.C. | 4 | $179 |
| Medtronic | 2 | $153 |
| Bristol Myers Squibb | 6 | $149 |
| Sirtex Medical Inc | 1 | $142 |
| Mirati Therapeutics, Inc. | 1 | $115 |
| Exelixis Inc. | 2 | $114 |
| Daiichi Sankyo Inc. | 6 | $104 |
| Pfizer | 8 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Merck | 4 | $84 |
| Sanofi | 3 | $83 |
| AbbVie | 3 | $74 |
| Genentech USA, Inc. | 3 | $71 |
| Lilly USA, LLC | 3 | $67 |
| Tempus AI, Inc | 1 | $66 |
| Johnson & Johnson | 3 | $55 |
| Astellas Pharma US Inc | 2 | $43 |
| Taiho Oncology, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Genmab U.S., Inc. | 1 | $29 |
| Stemline Therapeutics Inc. | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Array Biopharma Inc | 1 | $23 |
| Deciphera Pharmaceuticals Inc. | 1 | $23 |
| Bayer | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| EMD Serono, Inc. | 1 | $17 |
| Caris MPI, Inc. | 1 | $15 |
| AVEO Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIR-Spheres Microspheres$142
- OSTEOCOOL RF ABLATION SYSTEM$130
- XPOVIO$125
- OJJAARA$120
- KRAZATI$115
How this compares
$3,498 in reported general payments places this provider in the 50th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 11 | $21,651 |
| Imatinib Mesylate | 12 | $869 |
| Anastrozole | 26 | $496 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 16 | $242 |
| Hydroxyurea | 22 | $213 |
| Ondansetron OdtOndansetron | 19 | $211 |
| Dexamethasone | 34 | $170 |
| Prednisone | 15 | $59 |
| Potassium Chloride | 15 | $14 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in McAllen
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.